Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujatro Chakladar

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|June 29, 2022
Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its componentsRan Liao, Sujatro Chakladar, Margaret Gamalo
Journal of Biopharmaceutical Statistics|August 18, 2021
Estimands, Handling of Missing Data and Impact on Assumed Effect Size and Power in Pivotal COVID-19 Treatment TrialsSujatro Chakladar, Ran Liao, Margaret Gamalo
BMC Proceedings|December 19, 2009
A quantile-based method for association mapping of quantitative phenotypes: an application to rheumatoid arthritis phenotypesSaurabh Ghosh, Krishna Rao Sanapala, Abhik Ghosh, et al.
Contemporary Clinical Trials Communications|July 1, 2026
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trialAtul Malhotra, Daniel J Gottlieb, Vaishnavi Kundel, et al.
Sleep Medicine|August 7, 2025
Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesityChisom Kanu, Shraddha Shinde, Sujatro Chakladar, et al.
Biometrics|March 26, 2021
Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoringSujatro Chakladar, Samuel Rosin, Michael G Hudgens, et al.
Journal of Translational Autoimmunity|July 1, 2021
Baricitinib and primary biliary cholangitisStuart C Gordon, Sheri Trudeau, Arie Regev, et al.
Sleep Medicine|October 24, 2025
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weightAtul Malhotra, Ronald R Grunstein, Ali Azarbarzin, et al.
Journal of the American Heart Association|October 29, 2015
Reducing the Blood Pressure-Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and ControlShakia T Hardy, Laura R Loehr, Kenneth R Butler, et al.
Contemporary Clinical Trials|March 28, 2024
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trialAtul Malhotra, Josef Bednarik, Sujatro Chakladar, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|June 29, 2022
Win ratio approach for analyzing composite time-to-event endpoint with opposite treatment effects in its componentsRan Liao, Sujatro Chakladar, Margaret Gamalo
Journal of Biopharmaceutical Statistics|August 18, 2021
Estimands, Handling of Missing Data and Impact on Assumed Effect Size and Power in Pivotal COVID-19 Treatment TrialsSujatro Chakladar, Ran Liao, Margaret Gamalo
BMC Proceedings|December 19, 2009
A quantile-based method for association mapping of quantitative phenotypes: an application to rheumatoid arthritis phenotypesSaurabh Ghosh, Krishna Rao Sanapala, Abhik Ghosh, et al.
Contemporary Clinical Trials Communications|July 1, 2026
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trialAtul Malhotra, Daniel J Gottlieb, Vaishnavi Kundel, et al.
Sleep Medicine|August 7, 2025
Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesityChisom Kanu, Shraddha Shinde, Sujatro Chakladar, et al.
Biometrics|March 26, 2021
Inverse probability weighted estimators of vaccine effects accommodating partial interference and censoringSujatro Chakladar, Samuel Rosin, Michael G Hudgens, et al.
Journal of Translational Autoimmunity|July 1, 2021
Baricitinib and primary biliary cholangitisStuart C Gordon, Sheri Trudeau, Arie Regev, et al.
Sleep Medicine|October 24, 2025
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weightAtul Malhotra, Ronald R Grunstein, Ali Azarbarzin, et al.
Journal of the American Heart Association|October 29, 2015
Reducing the Blood Pressure-Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and ControlShakia T Hardy, Laura R Loehr, Kenneth R Butler, et al.
Contemporary Clinical Trials|March 28, 2024
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trialAtul Malhotra, Josef Bednarik, Sujatro Chakladar, et al.
Pageof 2